Gründer G, Bauer M. [Between efficacy and criticism: antidepressants in discourse]. Nervenarzt. 2025 96(2):117-118.
Gründer G, Bauknecht P, Schell S, Leopold K, Paulzen M, Leucht S. Identification and Rating of Treatment Goals in Schizophrenia: Delphi Process and Concordance Survey in Matched Physician-Patient Pairs. Patient Prefer Adherence. 2025 19:1029-1046.
Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2025 Sep 18. [Epub ahead of print]
Gründer G, Mertens L, Spangemacher M, Schmitz C. [Can antidepressants negatively alter the long-term course of depressive disorders?]. Nervenarzt. 2025 96(2):146-152. Epub 2025 Feb 24.
Hart XM, Amann F, Baumann P, Havemann-Reinecke U, Schoretsanitis G, Steimer W, Unterecker S, Zernig G, Gründer G, Hiemke C. How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP. Ther Drug Monit. 2025 47(2):199-210. Epub 2025 Feb 14.
Hartter N, Däumichen M, Schmidt C, Wolff M, Gründer G, Jungaberle H. [Acceptance of psilocybin-assisted therapy in German-speaking countries]. Nervenarzt. 2025 Feb 12. [Epub ahead of print]
Mlynek E, Tan X, Lammertz SE, Schaffrath S, Gründer G, Schneider F, Frodl T, Mathiak K, Gaebler AJ. Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia. Schizophr Bull. 2025 Apr 23. [Epub ahead of print] 15:153.
Schmitz C, Sammer G, Neumann E, Blecker C, Gründer G, Adolphi H, Lamadé EK, Pedraz-Petrozzi B. Functional resting state connectivity is differentially associated with IL-6 and TNF-α in depression and in healthy controls. Sci Rep. 2025 15(1):1769.
Schmitz CN, Hart XM, Spangemacher M, Roth JL, Lazarevic I, Oberthür G, Büsing KA, Becker R, Cumming P, Gründer G. Neurovascular coupling of striatal dopamine D receptor availability and perfusion using simultaneous PET/MR in humans. Neurosci Appl. 2025 3:104094.
Spangemacher M, Reinwald J, Adolphi H, Kärtner L, Mertens LJ, Schmitz CN, Gründer G. [Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment]. Nervenarzt. 2025 96(2):119-127. Epub 2025 Jan 16.
Spangemacher M, Schmitz C, Cumming P, Färber LV, Hart XM, Uchida H, Gründer G. The sense and nonsense of antipsychotic combinations: A model for dopamine D receptor occupancy. Transl Psychiatry. 2025 15(1):348.
Wolff M, Rutrecht H, Gründer G, Jungaberle A, Jungaberle H. Key competencies for psychedelic treatment in real-world mental health care settings. Gen Hosp Psychiatry. 2025 Sep 16. [Epub ahead of print] 97:11-24.
Wolff M, Rutrecht H, Mertens L, Meijer AA, Beck J, Pérez S, Gründer G, Dziobek I, Jungaberle H. Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe's general change mechanisms. Psychol Rev. 2025 Oct 9. [Epub ahead of print]
Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Med (New Rochelle). 2025 3(1):1-18.